We'll see. I would not characterize what I posted as anything close to gargantuan news. We've yet to see Phase 3 data on J&J's vaccine candidate, though there are rumors that it may be released pretty soon. If I recall correctly, the limited data that we have seen indicates that the J&J vaccine has 70-75% efficacy, versus @ 95% efficacy for the Pfizer and the Moderna viruses. 70-75% efficacy is better than nothing, but it still leaves one that is exposed to the SARS-CoV-2 virus a 1 in 4 chance of catching COVID-19.
There are also rumors that the Phase 3 data for NoraVax's vaccine candidate are pretty close to being released. IF both J&J's candidate and NoraVax's candidate prove to have high efficacy, and IF both companies can release the large quantity of vaccine doses that they have indicated are possible, then there is a high probability that most Americans can be vaccinated by the summer. There are a couple of really large IFs in the aforementioned, so I think any reaction to company releases should be tempered.
The AZ vaccine candidate is also in the mix, but despite
@interrobang's ranting about the FDA, it is AZ that screwed up their Phase 3 trial, not the FDA. AZ is basically re-doing their Phase 3 trial in the USA, with 30,000 participants. The latest timeline I saw on AZ's Phase 3 trial and the FDA is either the testing will be completed in April, or that's when they expect to be in a position to submit a proposal for an EUA to the FDA (I forget which; don't have time to look it up now). The AZ vaccine has been approved in the UK, but they have a lower threshold for what is required to get approval. India, Argentina, and Mexico have also approved the AZ vaccine, and the EU appears to be poised to do so this week or next week. In the original Phase 3 trial, which only featured @ 5,800 participants, the efficacy of the vaccine was shown to be @ 62%, which is even lower than the numbers listed above for J&J, and much lower than the Pfizer and Moderna numbers. There was a small subset of the original AZ Phase 3 trial that mistakenly was given a smaller dose of the first shot, and ended up showing an efficacy of 90%. Scientists have a lot of doubts that the 90% efficacy will appear in the larger Phase 3 trial that AZ is currently conducting, but only time will tell for sure.